Therapeutic use of soluble fas ligand ameliorates acute and recurrent herpetic stromal keratitis in mice

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 11, 2015, Pages 6377-6386

  Rogge, Megan ^a   Yin, Xiao Tang ^a   Godfrey, Lisa ^a   Lakireddy, Priya ^a   Potter, Chloe A ^a   Del Rosso, Chelsea R ^a   Stuart, Patrick M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cornea; Herpes simplex virus; Neutrophils

Indexed keywords

FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; FASLG PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; INFLAMMATORY INFILTRATE; MOUSE; NONHUMAN; PLAQUE ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; ULTRAVIOLET B RADIATION; VIRUS REACTIVATION; ACUTE DISEASE; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; CORNEA STROMA; DISEASE MODEL; DRUG EFFECTS; KERATITIS, HERPETIC; PATHOLOGY; VIROLOGY;

ACUTE DISEASE; ANIMALS; CORNEAL STROMA; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; HERPESVIRUS 1, HUMAN; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; RECURRENCE;

EID: 84943599601     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-16588     Document Type: Article

References (51)

1. Pepose JS, Leib DA, Stuart PM, Easty EL. Herpes simplex virus
2. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic Update Surv Ophthalmol. 2012;57:488-462.
3. Thomas J, Gangappa S, Kanangat S, Rouse BT. On the essentialinvolvement of neutrophils in the immunopathologic disease:herpetic stromal keratitis. J Immunol. 1997;158:1383-1391.
4. Maertzdorf J, Verjans GM, Remeijer L, van der Kooi A, Osterhaus AD. Restricted T cell receptor beta-chain variableregion protein use by cornea-derived CD4þ and CD8þ herpes simplex virus-specific T cells in patients with herpetic stromal keratitis. J Infect Dis. 2003;187:550-558.
5. Divito SJ, Hendricks RL. Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis. Invest Ophthalmol Vis Sci. 2008;49:1488-1495.
6. Denniston AK, Kottoor SH, Khan I, et al. Endogenous cortisol and TGF-beta in human aqueous humor contribute to ocular immune privilege by regulating dendritic cell function. J Immunol. 2011;186:305-311.
7. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy. 2007;92:50-57.
8. Koevary SB. Ocular immune privilege: a review. Clin Eye Vis Care. 2000;12:97-106.
9. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
10. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD-95- induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
11. Stuart PM, Griffith TS, Usui N, Pepose JS, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
12. Osawa H, Maruyama K, Streilein JW. CD95 ligand expression on corneal epithelium and endothelium influences the fates oforthotopic and heterotopic corneal allografts in mice. Invest Ophthalmol Vis Sci. 2004;45:1908-1915.
13. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nature Med. 1999;5:292-297.
14. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic TSP-1 and PEDF. Nature Med. 2002;8:349-357.
15. Stuart PM, Pan F, Plambeck S, Ferguson TA. Fas/Fas ligand interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci. 2003;44:93-98.
16. Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood. 1996; 87:3245-3254.
17. Morris, JE, Zobell S, Yin XT, et al. Mice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1. J Immunol. 2012;188:793-799.
18. Huang D, Hahne M, Schroeter M, et al. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL. Proc Natl Acad Sci U S A. 1999; 96:14871-14876.
19. Stuart PM, Yin XT, Plambeck S, Pan F, Ferguson TA. The role of Fas ligand as an effector molecule in corneal graft rejection. Eur J Immunol. 2005;35:2591-2597.
20. Keadle TL, Morrison LA, Morris JE, Pepose JS, Stuart PM. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. J Virol. 2002;76: 3615-3625.
21. Herndon JM, Stuart PM, Ferguson TA. Peripheral deletion of antigen-specific T cells leads to long-term tolerance mediated by CD8þ cytotoxic cells. J Immunol. 2005;174:4098-4104.
22. Stuart PM, Summers B, Morris JE, Morrison LA, Leib DA. CD8þ T cells control corneal disease following ocular infection with HSV-1. J Gen Virol. 2004;85:2055-2063.
23. Keadle TL, Laycock KA, Miller JK, et al. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J Infect Dis. 1997;176:331-338.
24. Shimeld C, Hill TJ, Blyth B, Easty D. An improved model of recurrent herpetic eye disease in mice. Curr Eye Res. 1989;8: 1193-1205.
25. West DM, Del Rosso CR, Yin XT, Stuart PM. CXCL1 but not IL-6 is required for recurrent herpetic stromal keratitis. J Immunol. 2014;192:1762-1767.
26. Stuart PM, Keadle TL. Recurrent herpetic stromal keratitis in mice, a model for studying human HSK. Clin Dev Immunol. 2012;2012:728480.
27. Smith TJ, Ackland-Berglund CE, Leib DA. Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice. J Virol. 2000;74:3598-3604.
28. Roychoudhury J, Herndon JM, Yin J, Apte RS, Ferguson TA. Targeting immune privilege to prevent pathogenic neovascularization. Invest Ophthalmol Vis Sci. 2010;51:3560-3566.
29. Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplant. 1997;64:1107-1111.
30. Dobbs ME, Strasser JE, Chu CF, Chalk C, Milligan GN. Clearance of herpes simplex virus type 2 by CD8þ T cells requires gamma interferon and either perforin- or Fasmediated cytolytic mechanisms. J Virol. 2005;79:14546-14554.
31. Rouvier E, Luciani M-F, Golstein P. Fas involvement in Caþindependent T cell-mediated cytotoxicity. J Exp Med. 1993; 177:195-200.
32. Liu ZX, Govindarajan S, Okamoto S, Dennert G. Fas-mediated apoptosis causes elimination of virus-specific cytotoxic T cells in the virus-infected liver. J Immunol. 2001;166:3035-3041.
33. Bryant-Hudson KM, Carr DJ. CXCL1-deficient mice are highly sensitive to pseudomonas aeruginosa but not herpes simplex virus type 1 corneal infection. Invest Ophthalmol Vis Sci. 2012;53:6785-6792.
34. Carlson EC, Lin M, Liu CY, Kao WW, Perez VL, Pearlman E. CXCL1/KC and CXCL5/LIX are selectively produced by corneal fibroblasts and mediate neutrophil infiltration to the corneal stroma in LPS keratitis. J Leukoc Biol. 2007;81:786-792.
35. Chintakuntlawar AV, Chodosh J. Chemokine CXCL1/KC and its receptor CXCR2 are responsible for neutrophil chemotaxis in adenoviral keratitis. J Interferon Cytokine Res. 2009;29:657-666.
36. Kunes P, Krejsek J, Brtko M, Mandak J, Kolackova M, Trojackova Kudlova M, Andrys C. Neutrophil apoptosis by Fas/FasL: harmful or advantageous in cardiac surgery? Thorac Cardiovasc Surg. 2009;57:1-6.
37. Sugi N, Whiston EA, Ksander BR, Gregory MS. Increased resistance to Staphylococcus aureus endophthalmitis in BALB/ c mice: Fas ligand is required for resolution of inflammation but not for bacterial clearance. Infect Immun. 2013;81:2217-2225.
38. O’Donnell JA, Kennedy CL, Pellegrini M, et al. Fas regulates neutrophil lifespan during viral and bacterial infection. J Leukoc Biol. 2015;97:321-326.
39. Conrady CD, Zheng M, Stone DU, Carr DJ. CD8þ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis. J Immunol. 2012; 189:425-432.
40. Frank GM, Buela KA, Maker DM, Harvey SA, Hendricks RL. Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea. J Immunol. 2012;188:1350-1359.
41. Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-related apoptsos-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol. 2005;45:1018-1024.
42. Raftery MJ, Behrens CK, Müller A, Krammer PH, Walczak H, Schönrich G. Herpes simplex virus type 1 infection of activated cytotoxic T cells: induction of fratricide as a mechanism of viral immune evasion. J Exp Med. 1999;190: 1103-1114.
43. Griffith TS, Brincks EL, Gurung P, Kucaba TA, Ferguson TA. Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8þ T cells. J Immunol. 2011;186:791-798.
44. Munjal VP, Dhir SP, Jain IS, Gangwar DN, D’souza M. Topical corticosteroids and cataract. Indian J Ophthalmol. 1984;32: 478-480.
45. Dada T, Nair S, Dhawan M. Steroid-induced glaucoma. J Curr Glaucoma Prac. 2009;3:33-38.
46. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505-512.
47. Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;71:603-610.
48. Wilhelmus KR, Mitchell BM, Jones DB. Photographic monitoring of herpes simplex virus keratitis during anti-inflammatory treatment. Arch Ophthalmol. 2011;129:252-253.
49. Duan R, de Vries RD, van Dun JM, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis. 2009;200:1402-1414.
50. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61:577-581.
51. Stuart PM, Pan F, Yin XT, Haskova Z, Plambeck S, Ferguson TA. Effect of metalloprotease inhibitors on corneal allograft survival. Invest Ophthalmol Vis Sci. 2004;45:1169-1173.